AbolerIS Pharma

Monoclonal antibodies
#AbolerIS Pharma #Arthritis #Autoimmune disease #Financing #Monoclonal antibodies

€27.3M to advance monoclonal antibody for autoimmune diseases

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases. Read More

#Business & Investment #News